Zykadia

Ceritinib (INN,[2] trade name Zykadia /zakedi/ zy-KAY-dee-, from Novartis) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC).[3] It was developed by Novartis and received FDA approval for use in April 2014.[3].Ceritinib is also sold under the brand name Spexib in few countries by Novartis . Contents 1 Medical uses 2 Adverse effects 3 Interactions 4 Pharmacology 4.1 Mechanism of action 5 Research and de... [wikipedia]